![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
La Jolla Pharmaceutical Company | NASDAQ:LJPC | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.23 | 6.54 | 6.25 | 0 | 01:00:00 |
|
|
|
|
|
|
|
☒
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
☐
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
|
|
|
California
|
|
33-0361285
|
|||
(State or other jurisdiction of incorporation or organization)
|
|
(I.R.S. Employer Identification No.)
|
|||
|
|
|
|
|
|
4550 Towne Centre Court,
|
San Diego,
|
CA
|
|
|
92121
|
(Address of principal executive offices)
|
|
(Zip Code)
|
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
||||||
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
||
|
Common Stock, par value $0.0001 per share
|
|
LJPC
|
|
The
|
Nasdaq
|
Capital Market
|
|
|
|
|
Large accelerated filer
|
☐
|
Accelerated filer
|
☒
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
☒
|
|
|
Emerging growth company
|
☐
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
June 30,
2020 |
|
December 31,
2019 |
||||
|
(Unaudited)
|
|
|
||||
ASSETS
|
|
|
|
||||
Current assets:
|
|
|
|
||||
Cash
|
$
|
68,353
|
|
|
$
|
87,820
|
|
Short-term investments
|
3,062
|
|
|
—
|
|
||
Accounts receivable, net
|
1,843
|
|
|
2,960
|
|
||
Inventory, net
|
3,120
|
|
|
2,211
|
|
||
Prepaid expenses and other current assets
|
2,792
|
|
|
4,467
|
|
||
Total current assets
|
79,170
|
|
|
97,458
|
|
||
Property and equipment, net
|
12,827
|
|
|
18,389
|
|
||
Right-of-use lease asset
|
14,792
|
|
|
15,491
|
|
||
Restricted cash
|
606
|
|
|
909
|
|
||
Total assets
|
$
|
107,395
|
|
|
$
|
132,247
|
|
|
|
|
|
||||
LIABILITIES AND SHAREHOLDERS’ DEFICIT
|
|
|
|
||||
Current liabilities:
|
|
|
|
||||
Accounts payable
|
$
|
2,481
|
|
|
$
|
4,177
|
|
Accrued expenses
|
6,772
|
|
|
9,312
|
|
||
Accrued payroll and related expenses
|
5,741
|
|
|
8,332
|
|
||
Lease liability, current portion
|
2,890
|
|
|
2,766
|
|
||
Total current liabilities
|
17,884
|
|
|
24,587
|
|
||
Lease liability, less current portion
|
25,000
|
|
|
26,481
|
|
||
Deferred royalty obligation, net
|
124,406
|
|
|
124,379
|
|
||
Other noncurrent liabilities
|
15,317
|
|
|
12,790
|
|
||
Total liabilities
|
182,607
|
|
|
188,237
|
|
||
Commitments and contingencies (Note 6)
|
|
|
|
||||
Shareholders’ deficit:
|
|
|
|
||||
Common Stock, $0.0001 par value; 100,000,000 shares authorized,
27,358,611 and 27,195,469 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively
|
3
|
|
|
3
|
|
||
Series C-12 Convertible Preferred Stock, $0.0001 par value; 11,000 shares authorized, 3,906 shares issued and outstanding at June 30, 2020 and December 31, 2019; and liquidation preference of $3,906 at June 30, 2020 and December 31, 2019
|
3,906
|
|
|
3,906
|
|
||
Additional paid-in capital
|
982,393
|
|
|
977,432
|
|
||
Accumulated deficit
|
(1,061,514
|
)
|
|
(1,037,331
|
)
|
||
Total shareholders’ deficit
|
(75,212
|
)
|
|
(55,990
|
)
|
||
Total liabilities and shareholders’ deficit
|
$
|
107,395
|
|
|
$
|
132,247
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2020
|
|
2019
|
|
2020
|
|
2019
|
||||||||
Revenue
|
|
|
|
|
|
|
|
||||||||
Net product sales
|
$
|
5,805
|
|
|
$
|
5,703
|
|
|
$
|
13,396
|
|
|
$
|
10,098
|
|
Total revenue
|
5,805
|
|
|
5,703
|
|
|
13,396
|
|
|
10,098
|
|
||||
Operating expenses
|
|
|
|
|
|
|
|
||||||||
Cost of product sales
|
808
|
|
|
551
|
|
|
1,524
|
|
|
1,051
|
|
||||
Research and development
|
8,781
|
|
|
22,043
|
|
|
17,964
|
|
|
43,287
|
|
||||
Selling, general and administrative
|
8,677
|
|
|
11,323
|
|
|
16,829
|
|
|
23,643
|
|
||||
Total operating expenses
|
18,266
|
|
|
33,917
|
|
|
36,317
|
|
|
67,981
|
|
||||
Loss from operations
|
(12,461
|
)
|
|
(28,214
|
)
|
|
(22,921
|
)
|
|
(57,883
|
)
|
||||
Other income (expense)
|
|
|
|
|
|
|
|
||||||||
Interest expense
|
(2,470
|
)
|
|
(2,806
|
)
|
|
(4,876
|
)
|
|
(5,535
|
)
|
||||
Interest income
|
32
|
|
|
604
|
|
|
222
|
|
|
1,317
|
|
||||
Other income—related party
|
—
|
|
|
—
|
|
|
4,085
|
|
|
—
|
|
||||
Other expense
|
(693
|
)
|
|
—
|
|
|
(693
|
)
|
|
—
|
|
||||
Total other income (expense), net
|
(3,131
|
)
|
|
(2,202
|
)
|
|
(1,262
|
)
|
|
(4,218
|
)
|
||||
Net loss
|
$
|
(15,592
|
)
|
|
$
|
(30,416
|
)
|
|
$
|
(24,183
|
)
|
|
$
|
(62,101
|
)
|
Net loss per share, basic and diluted
|
$
|
(0.57
|
)
|
|
$
|
(1.12
|
)
|
|
$
|
(0.89
|
)
|
|
$
|
(2.29
|
)
|
Weighted-average common shares outstanding, basic and diluted
|
27,326
|
|
|
27,108
|
|
|
27,282
|
|
|
27,071
|
|
|
|
Series C-12
Convertible
Preferred Stock
|
|
Series F
Convertible
Preferred Stock
|
|
Common
Stock
|
|
Additional
Paid-in
Capital
|
|
Accumulated
Deficit
|
|
Total
Shareholders’
(Deficit)
Equity
|
|||||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
|
|
||||||||||||||||||
Balance at December 31, 2019
|
|
4
|
|
|
$
|
3,906
|
|
|
—
|
|
|
$
|
—
|
|
|
27,195
|
|
|
$
|
3
|
|
|
$
|
977,432
|
|
|
$
|
(1,037,331
|
)
|
|
$
|
(55,990
|
)
|
Share-based compensation expense
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
2,407
|
|
|
—
|
|
|
2,407
|
|
||||||
Issuance of common stock under 2013 Equity Plan
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
44
|
|
|
—
|
|
|
305
|
|
|
—
|
|
|
305
|
|
||||||
Issuance of common stock under ESPP
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
38
|
|
|
—
|
|
|
200
|
|
|
—
|
|
|
200
|
|
||||||
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(8,591
|
)
|
|
(8,591
|
)
|
||||||
Balance at March 31, 2020
|
|
4
|
|
|
3,906
|
|
|
—
|
|
|
—
|
|
|
27,277
|
|
|
3
|
|
|
980,344
|
|
|
(1,045,922
|
)
|
|
(61,669
|
)
|
||||||
Share-based compensation expense
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
1,590
|
|
|
—
|
|
|
1,590
|
|
||||||
Issuance of common stock under 2013 Equity Plan
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
50
|
|
|
—
|
|
|
300
|
|
|
—
|
|
|
300
|
|
||||||
Issuance of common stock under ESPP
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
32
|
|
|
—
|
|
|
159
|
|
|
—
|
|
|
159
|
|
||||||
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(15,592
|
)
|
|
(15,592
|
)
|
||||||
Balance at June 30, 2020
|
|
4
|
|
|
$
|
3,906
|
|
|
—
|
|
|
$
|
—
|
|
|
27,359
|
|
|
$
|
3
|
|
|
$
|
982,393
|
|
|
$
|
(1,061,514
|
)
|
|
$
|
(75,212
|
)
|
|
|
Series C-12
Convertible
Preferred Stock
|
|
Series F
Convertible
Preferred Stock
|
|
Common
Stock
|
|
Additional
Paid-in
Capital
|
|
Accumulated
Deficit
|
|
Total
Shareholders’
(Deficit)
Equity
|
|||||||||||||||||||||
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
Shares
|
|
Amount
|
|
|
|
||||||||||||||||||
Balance at December 31, 2018
|
|
4
|
|
|
$
|
3,906
|
|
|
3
|
|
|
$
|
2,737
|
|
|
26,259
|
|
|
$
|
3
|
|
|
$
|
950,258
|
|
|
$
|
(920,983
|
)
|
|
$
|
35,921
|
|
Share-based compensation expense
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,782
|
|
|
—
|
|
|
6,782
|
|
||||||
Issuance of common stock under ESPP
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
52
|
|
|
—
|
|
|
283
|
|
|
—
|
|
|
283
|
|
||||||
Issuance of common stock for conversion of Series F Preferred Stock
|
|
—
|
|
|
—
|
|
|
(3
|
)
|
|
(2,737
|
)
|
|
782
|
|
|
—
|
|
|
2,737
|
|
|
—
|
|
|
—
|
|
||||||
Cumulative-effect adjustment from adoption of ASU 2018-07
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(160
|
)
|
|
160
|
|
|
—
|
|
||||||
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(31,685
|
)
|
|
(31,685
|
)
|
||||||
Balance at March 31, 2019
|
|
4
|
|
|
3,906
|
|
|
—
|
|
|
—
|
|
|
27,093
|
|
|
3
|
|
|
959,900
|
|
|
(952,508
|
)
|
|
11,301
|
|
||||||
Share-based compensation expense
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
6,321
|
|
|
—
|
|
|
6,321
|
|
||||||
Issuance of common stock under ESPP
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
32
|
|
|
—
|
|
|
201
|
|
|
—
|
|
|
201
|
|
||||||
Net loss
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
—
|
|
|
(30,416
|
)
|
|
(30,416
|
)
|
||||||
Balance at June 30, 2019
|
|
4
|
|
|
$
|
3,906
|
|
|
—
|
|
|
$
|
—
|
|
|
27,125
|
|
|
$
|
3
|
|
|
$
|
966,422
|
|
|
$
|
(982,924
|
)
|
|
$
|
(12,593
|
)
|
|
Six Months Ended June 30,
|
||||||
|
2020
|
|
2019
|
||||
Operating activities
|
|
|
|
||||
Net loss
|
$
|
(24,183
|
)
|
|
$
|
(62,101
|
)
|
Adjustments to reconcile net loss to net cash used for operating activities:
|
|
|
|
||||
Share-based compensation expense
|
3,997
|
|
|
13,103
|
|
||
Depreciation and amortization expense
|
1,798
|
|
|
2,263
|
|
||
Loss on disposal of equipment
|
904
|
|
|
15
|
|
||
Unrealized gains on short-term investments
|
(63
|
)
|
|
—
|
|
||
Non-cash interest expense
|
3,392
|
|
|
4,678
|
|
||
Non-cash rent expense
|
699
|
|
|
639
|
|
||
Changes in operating assets and liabilities:
|
|
|
|
||||
Accounts receivable, net
|
1,117
|
|
|
(512
|
)
|
||
Inventory, net
|
(909
|
)
|
|
52
|
|
||
Prepaid expenses and other current assets
|
1,675
|
|
|
22
|
|
||
Accounts payable
|
(1,696
|
)
|
|
(3,664
|
)
|
||
Accrued expenses
|
(3,378
|
)
|
|
974
|
|
||
Accrued payroll and related expenses
|
(2,591
|
)
|
|
(3,429
|
)
|
||
Lease liability
|
(1,357
|
)
|
|
(1,241
|
)
|
||
Net cash used for operating activities
|
(20,595
|
)
|
|
(49,201
|
)
|
||
Investing activities
|
|
|
|
||||
Proceeds from the sale of property and equipment
|
2,860
|
|
|
—
|
|
||
Purchases of property and equipment
|
—
|
|
|
(441
|
)
|
||
Purchases of short-term investments
|
(2,999
|
)
|
|
—
|
|
||
Net cash used for investing activities
|
(139
|
)
|
|
(441
|
)
|
||
Financing activities
|
|
|
|
||||
Net proceeds from issuance of common stock under 2013 Equity Plan
|
605
|
|
|
—
|
|
||
Net proceeds from issuance of common stock under ESPP
|
359
|
|
|
484
|
|
||
Net cash provided by financing activities
|
964
|
|
|
484
|
|
||
Net decrease in cash and restricted cash
|
(19,770
|
)
|
|
(49,158
|
)
|
||
Cash and restricted cash at beginning of period
|
88,729
|
|
|
173,513
|
|
||
Cash and restricted cash at end of period
|
$
|
68,959
|
|
|
$
|
124,355
|
|
Supplemental disclosure of non-cash investing and financing activities:
|
|
|
|
||||
Conversion of Series F Convertible Preferred Stock into common stock
|
$
|
—
|
|
|
$
|
2,737
|
|
Cumulative-effect adjustment from adoption of ASU 2018-07
|
$
|
—
|
|
|
$
|
(160
|
)
|
Initial recognition of right-of-use lease asset
|
$
|
—
|
|
|
$
|
16,798
|
|
Reconciliation of cash and restricted cash to the condensed consolidated balance sheets
|
|||||||
Cash
|
$
|
68,353
|
|
|
$
|
123,446
|
|
Restricted cash
|
606
|
|
|
909
|
|
||
Total cash and restricted cash
|
$
|
68,959
|
|
|
$
|
124,355
|
|
|
U.S. Net Product Sales
|
|
Accounts Receivable
|
|||||
|
Three Months Ended June 30, 2020
|
|
Six Months Ended June 30, 2020
|
|
As of June 30, 2020
|
|||
Customer A
|
38
|
%
|
|
38
|
%
|
|
22
|
%
|
Customer B
|
33
|
%
|
|
31
|
%
|
|
41
|
%
|
Customer C
|
25
|
%
|
|
29
|
%
|
|
33
|
%
|
Total
|
96
|
%
|
|
98
|
%
|
|
96
|
%
|
•
|
Chargebacks—Chargebacks are discounts the Company provides to distributors in the event that the sales prices to end users are below the distributors’ acquisition price. This may occur due to a direct contract with a health system, a group purchasing organization (“GPO”) agreement or a sale to a government facility. Chargebacks are estimated based on known chargeback rates and recorded as a reduction of revenue on delivery to the Company’s customers.
|
•
|
Discounts—The Company offers customers various forms of incentives and consideration, including prompt-pay and other discounts. The Company estimates discounts primarily based on contractual terms. These discounts are recorded as a reduction of revenue on delivery to the Company’s customers.
|
•
|
Returns—The Company offers customers a limited right of return, generally for damaged or expired product. The Company estimates returns based on an internal analysis, which includes actual experience. The estimates for returns are recorded as a reduction of revenue on delivery to the Company’s customers.
|
•
|
Administrative Fees—The Company pays administrative fees to GPOs for services and access to data. Additionally, the Company pays an Industrial Funding Fee as part of the U.S. General Services Administration’s Federal Supply Schedules program. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the applicable GPO or government agency.
|
|
|
June 30,
2020 |
|
December 31,
2019 |
||||
Work-in-process
|
|
$
|
1,801
|
|
|
$
|
1,505
|
|
Finished goods
|
|
1,319
|
|
|
706
|
|
||
Total inventory, net
|
|
$
|
3,120
|
|
|
$
|
2,211
|
|
|
|
June 30,
2020 |
|
December 31,
2019 |
||||
Leasehold improvements
|
|
$
|
14,504
|
|
|
$
|
14,504
|
|
Furniture and fixtures
|
|
2,549
|
|
|
2,598
|
|
||
Computer hardware
|
|
1,296
|
|
|
1,296
|
|
||
Software
|
|
733
|
|
|
733
|
|
||
Lab equipment
|
|
—
|
|
|
9,665
|
|
||
Total property and equipment, gross
|
|
19,082
|
|
|
28,796
|
|
||
Accumulated depreciation and amortization
|
|
(6,255
|
)
|
|
(10,407
|
)
|
||
Total property and equipment, net
|
|
$
|
12,827
|
|
|
$
|
18,389
|
|
|
|
June 30,
2020 |
|
December 31,
2019 |
||||
Accrued interest expense
|
|
$
|
3,530
|
|
|
$
|
2,692
|
|
Accrued manufacturing costs
|
|
1,369
|
|
|
1,339
|
|
||
Accrued clinical study costs
|
|
815
|
|
|
3,496
|
|
||
Accrued other
|
|
1,058
|
|
|
1,785
|
|
||
Total accrued expenses
|
|
$
|
6,772
|
|
|
$
|
9,312
|
|
2020
|
$
|
2,039
|
|
2021
|
4,174
|
|
|
2022
|
4,294
|
|
|
2023
|
4,417
|
|
|
2024
|
4,544
|
|
|
Thereafter
|
13,590
|
|
|
Total future minimum lease payments
|
33,058
|
|
|
Less: discount
|
(5,168
|
)
|
|
Total lease liability
|
$
|
27,890
|
|
|
Equity Awards
|
|
Weighted-
average
Exercise Price
per Share
|
|
Weighted-
average
Remaining
Contractual
Term
|
|
Aggregate
Intrinsic Value |
|||||
Outstanding at December 31, 2019
|
5,616,840
|
|
|
$
|
19.50
|
|
|
|
|
|
||
Granted
|
806,923
|
|
|
$
|
5.27
|
|
|
|
|
|
||
Exercised
|
(94,219
|
)
|
|
$
|
6.42
|
|
|
|
|
|
||
Cancelled/forfeited
|
(2,883,533
|
)
|
|
$
|
19.43
|
|
|
|
|
|
||
Outstanding at June 30, 2020
|
3,446,011
|
|
|
$
|
16.59
|
|
|
5.87 years
|
|
$
|
35,037
|
|
Exercisable at June 30, 2020
|
2,144,609
|
|
|
$
|
20.84
|
|
|
4.27 years
|
|
$
|
—
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||
|
2020
|
|
2019
|
|
2020
|
|
2019
|
||||||||
Research and development
|
$
|
964
|
|
|
$
|
3,960
|
|
|
$
|
2,527
|
|
|
$
|
7,893
|
|
Selling, general and administrative
|
626
|
|
|
2,361
|
|
|
1,470
|
|
|
5,210
|
|
||||
Total share-based compensation expense
|
$
|
1,590
|
|
|
$
|
6,321
|
|
|
$
|
3,997
|
|
|
$
|
13,103
|
|
a
|
U.S.: GIAPREZA is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock.
|
|
European Union: GIAPREZA is indicated for the treatment of refractory hypotension in adults with septic or other distributive shock who remain hypotensive despite adequate volume restitution and application of catecholamines and other available vasopressor therapies.
|
b
|
U.S.: XERAVA is a novel fluorocycline of the tetracycline class of antibacterials for the treatment of complicated intra-abdominal infections (“cIAI”) in patients 18 years of age and older.
European Union: XERAVA is indicated for the treatment of cIAI in adults.
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||||||||||
|
2020
|
|
2019
|
|
Change
|
|
2020
|
|
2019
|
|
Change
|
||||||||||||
Net product sales
|
$
|
5,805
|
|
|
$
|
5,703
|
|
|
$
|
102
|
|
|
$
|
13,396
|
|
|
$
|
10,098
|
|
|
$
|
3,298
|
|
Cost of product sales
|
(808
|
)
|
|
(551
|
)
|
|
(257
|
)
|
|
(1,524
|
)
|
|
(1,051
|
)
|
|
(473
|
)
|
||||||
Research and development expense
|
(8,781
|
)
|
|
(22,043
|
)
|
|
13,262
|
|
|
(17,964
|
)
|
|
(43,287
|
)
|
|
25,323
|
|
||||||
Selling, general and administrative expense
|
(8,677
|
)
|
|
(11,323
|
)
|
|
2,646
|
|
|
(16,829
|
)
|
|
(23,643
|
)
|
|
6,814
|
|
||||||
Other income (expense), net
|
(3,131
|
)
|
|
(2,202
|
)
|
|
(929
|
)
|
|
(1,262
|
)
|
|
(4,218
|
)
|
|
2,956
|
|
||||||
Net loss
|
$
|
(15,592
|
)
|
|
$
|
(30,416
|
)
|
|
$
|
14,824
|
|
|
$
|
(24,183
|
)
|
|
$
|
(62,101
|
)
|
|
$
|
37,918
|
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||||||||||
|
2020
|
|
2019
|
|
Change
|
|
2020
|
|
2019
|
|
Change
|
||||||||||||
Non-personnel expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
GIAPREZA
|
$
|
1,762
|
|
|
$
|
1,623
|
|
|
$
|
139
|
|
|
$
|
2,843
|
|
|
$
|
3,021
|
|
|
$
|
(178
|
)
|
LJPC-0118
|
404
|
|
|
113
|
|
|
291
|
|
|
917
|
|
|
1,135
|
|
|
(218
|
)
|
||||||
LJPC-401
|
—
|
|
|
4,880
|
|
|
(4,880
|
)
|
|
1,531
|
|
|
8,795
|
|
|
(7,264
|
)
|
||||||
Other programs
|
—
|
|
|
2,280
|
|
|
(2,280
|
)
|
|
—
|
|
|
3,843
|
|
|
(3,843
|
)
|
||||||
Facility
|
1,124
|
|
|
1,785
|
|
|
(661
|
)
|
|
2,560
|
|
|
3,576
|
|
|
(1,016
|
)
|
||||||
Other
|
—
|
|
|
992
|
|
|
(992
|
)
|
|
474
|
|
|
1,918
|
|
|
(1,444
|
)
|
||||||
Total non-personnel expense
|
$
|
3,290
|
|
|
$
|
11,673
|
|
|
$
|
(8,383
|
)
|
|
$
|
8,325
|
|
|
$
|
22,288
|
|
|
$
|
(13,963
|
)
|
Personnel expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Salaries, bonuses and benefits
|
4,527
|
|
|
6,410
|
|
|
(1,883
|
)
|
|
7,112
|
|
|
13,106
|
|
|
(5,994
|
)
|
||||||
Share-based compensation expense
|
964
|
|
|
3,960
|
|
|
(2,996
|
)
|
|
2,527
|
|
|
7,893
|
|
|
(5,366
|
)
|
||||||
Total personnel expense
|
$
|
5,491
|
|
|
$
|
10,370
|
|
|
$
|
(4,879
|
)
|
|
$
|
9,639
|
|
|
$
|
20,999
|
|
|
$
|
(11,360
|
)
|
Total research and development expense
|
$
|
8,781
|
|
|
$
|
22,043
|
|
|
$
|
(13,262
|
)
|
|
$
|
17,964
|
|
|
$
|
43,287
|
|
|
$
|
(25,323
|
)
|
|
Three Months Ended June 30,
|
|
Six Months Ended June 30,
|
||||||||||||||||||||
|
2020
|
|
2019
|
|
Change
|
|
2020
|
|
2019
|
|
Change
|
||||||||||||
Non-personnel expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Professional fees
|
$
|
1,356
|
|
|
$
|
1,139
|
|
|
$
|
217
|
|
|
$
|
2,227
|
|
|
$
|
2,095
|
|
|
$
|
132
|
|
Sales and marketing
|
588
|
|
|
1,471
|
|
|
(883
|
)
|
|
1,811
|
|
|
3,492
|
|
|
(1,681
|
)
|
||||||
Facility
|
554
|
|
|
393
|
|
|
161
|
|
|
1,047
|
|
|
773
|
|
|
274
|
|
||||||
Other
|
339
|
|
|
595
|
|
|
(256
|
)
|
|
925
|
|
|
1,187
|
|
|
(262
|
)
|
||||||
Total non-personnel expense
|
$
|
2,837
|
|
|
$
|
3,598
|
|
|
$
|
(761
|
)
|
|
$
|
6,010
|
|
|
$
|
7,547
|
|
|
$
|
(1,537
|
)
|
Personnel expenses:
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||
Salaries, bonuses and benefits
|
5,214
|
|
|
5,364
|
|
|
(150
|
)
|
|
9,349
|
|
|
10,886
|
|
|
(1,537
|
)
|
||||||
Share-based compensation expense
|
626
|
|
|
2,361
|
|
|
(1,735
|
)
|
|
1,470
|
|
|
5,210
|
|
|
(3,740
|
)
|
||||||
Total personnel expense
|
$
|
5,840
|
|
|
$
|
7,725
|
|
|
$
|
(1,885
|
)
|
|
$
|
10,819
|
|
|
$
|
16,096
|
|
|
$
|
(5,277
|
)
|
Total selling, general and administrative expense
|
$
|
8,677
|
|
|
$
|
11,323
|
|
|
$
|
(2,646
|
)
|
|
$
|
16,829
|
|
|
$
|
23,643
|
|
|
$
|
(6,814
|
)
|
|
|
|
Exhibit No.
|
|
Exhibit Description
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
|
||
|
|
|
101.INS
|
|
XBRL Instance Document
|
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document
|
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
|
|
La Jolla Pharmaceutical Company
|
|
|
|
|
Date:
|
August 6, 2020
|
By:
|
/s/ Larry Edwards
|
|
|
|
Larry Edwards
|
|
|
|
President and Chief Executive Officer
|
|
|
|
(Principal Executive Officer)
|
|
|
|
|
|
|
|
/s/ Michael Hearne
|
|
|
|
Michael Hearne
|
|
|
|
Chief Financial Officer
|
|
|
|
(Principal Financial and Accounting Officer)
|
1 Year La Jolla Pharmaceutical Chart |
1 Month La Jolla Pharmaceutical Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions